

Oncology Clinical Pathways

Basal Cell Carcinoma

March 2024 – V1.2024



Choose **VA**



SHOULDER to SHOULDER
Every Step of the Way

VA



U.S. Department
of Veterans Affairs

Table of Contents

Presumptive Conditions	3
Systemic First Line	4
Metastatic Second Line	5
Molecular Testing Table	6



Choose **VA**



SHOULDER to SHOULDER
Every Step of the Way

VA



U.S. Department
of Veterans Affairs

Basal Cell Carcinoma – Presumptive Conditions

VA automatically presumes that certain disabilities were caused by military service. This is because of the unique circumstances of a specific Veteran's military service. If a presumed condition is diagnosed in a Veteran within a certain group, they can be awarded disability compensation.

- Basal Cell Carcinoma is currently not a presumptive condition

For more information, please visit [U.S. Department of Veterans Affairs - Presumptive Disability Benefits \(va.gov\)](https://www.va.gov/presumptive-disability-benefits/)



Choose **VA**




SHOULDER to SHOULDER
Every Step of the Way

VA



U.S. Department
of Veterans Affairs

Basal Cell Carcinoma – Systemic First Line




Clinical trial(s) always considered on pathway. Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

^a **Systemic First Line** patient not a candidate for definitive local medical, surgical, or radiation treatment as determined by multidisciplinary discussion; includes systemic imaging as clinically indicated if not already performed

^b **Candidate for Immunotherapy** patient without active autoimmune disease, primary immune deficiency, concurrent immunosuppression (including prednisone equivalent >10mg/day) or prior allogeneic hematopoietic stem cell transplantation/solid organ transplant

^c **Candidate for Hedgehog Inhibitor Therapy** inability to tolerate oral medication, pregnancy, breast feeding status may exclude patient from treatment, or potential for fertility concerns

Basal Cell Carcinoma – Metastatic Second Line



Clinical trial(s) always considered on pathway. Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

^a **Candidate for Immunotherapy** patient without active autoimmune disease, primary immune deficiency, concurrent immunosuppression (including prednisone equivalent >10mg/day) or prior allogeneic hematopoietic stem cell transplantation/solid organ transplant

^b **Hedgehog Inhibitor Therapy** patient inability to tolerate oral medication, pregnancy, breast feeding status may exclude patient from treatment, or potential for fertility concerns

Basal Cell Carcinoma – Molecular Testing Table

Eligibility	Test Category	Test Type	Recommended Vendors	NPOP Coverage	Specimen Type
Basal Cell Carcinoma	No molecular testing is currently required for standard prognostication and therapy.				

